Furthermore, the AUCs using EphA2-NF, CA19-9, or EphA2-NF + CA19-9 were 0.83, 0.85, and 0.94, respectively, for early-stage pancreatic cancer (stage I/II; Fig. 3F), and 0.93, 0.91, and 0.99, respectively, for late-stage pancreatic cancer (stage III/IV; Fig. 3G). This evidence concerns the gene NFASC and pancreatic neoplasm.